Revenue segments as reported by the company.

Subscription services

Professional services and other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Sales and marketing

General and admin

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veeva Systems

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Veeva Systems reports robust Q1 earnings, eyes growth opportunities

Veeva Systems delivered strong financial performance in Q1 2023, driven by robust execution and competitive wins. The company's focus on innovation, AI capabilities, and the transition to Vault CRM presents significant growth opportunities. However, challenges in the funding environment and customer migrations pose potential hurdles.

Veeva exceeds Q2 expectations, anticipates growth in clinical and data business

Veeva's Q2 performance exceeded expectations, leading to an increase in full-year guidance. The company's strengths lie in strong clinical activity, customer wins, and a focus on product excellence. However, challenges include migration costs, competitive landscape considerations, and marketing spend scrutiny. Veeva sees opportunities in M&A, minimal impact from R&D trends, and expansion of Veeva Link.

Veeva Systems surpasses Q3 expectations, eyes clinical data opportunity

Veeva Systems delivered a strong Q3 performance, with solid revenue and operating income. While facing challenges in billings and macroeconomic uncertainties, the company remains confident in its revenue target for fiscal year '25. The commitment from major enterprises and the potential in clinical data present significant opportunities for future growth.

Veeva Systems reports strong Q4 performance and forecasts $2.8B revenue

Veeva Systems showcases strong performance and strategic planning with revenue growth expectations of at least 15% in fiscal '24 and '25.
Positive feedback on product transitions and development, along with specialized sales teams, highlights market acceptance and innovation.
Challenges include short-term revenue impacts from timing-related issues and macro environment effects on customer spending.
Opportunities lie in revenue growth forecasts, product innovation, and market differentiation through new offerings and strategic deals.

Veeva Systems reports robust Q1 revenue growth and strategic focus

Veeva Systems' Q1 performance reflects strong revenue growth and a focus on customer-centric innovation. The company faces challenges in project scrutiny and competition but has opportunities in new product monetization and segment expansion.

Veeva Systems excels in Q2, eyes disciplined growth and innovation

Veeva Systems showcased robust financial performance, exceeding revenue and operating income targets, with a strong focus on customer success and product excellence.
While facing challenges such as migration costs and regulatory impacts, Veeva is well-positioned to leverage opportunities in disciplined M&A and product innovation.
The company's strategic growth initiatives, including Veeva Link expansion and CRM platform enhancements, aim to drive continued success and value for customers.

Veeva Systems posts solid Q3 results, eyes growth opportunities

Veeva Systems delivered a strong Q3 performance with solid revenue and operating income, showcasing financial stability and growth potential.
Despite challenges like trimmed billings and deal delays, Veeva remains confident in its fiscal year '25 revenue target, emphasizing strategic focus and operational efficiency.
The company's strengths in innovative products, strong partnerships, and global support ecosystem position it well for future growth and market leadership.
Opportunities in customer migration, AI integration, and market demand present avenues for Veeva to drive revenue growth and enhance its competitive positioning in the industry.

Veeva Systems excels in Q4 earnings, poised for strategic growth

Veeva Systems delivered strong financial performance in Q4 2024, showcasing revenue growth, operating income efficiency, and strategic product advancements.
The company's focus on innovation, customer success, and disciplined financial guidance positions it well for future growth and market leadership.
While facing challenges related to market uncertainties and operational considerations, Veeva remains resilient and poised to capitalize on opportunities for expansion and differentiation.
Overall, Veeva's Q4 earnings call highlights a balanced approach to growth, operational excellence, and strategic decision-making in a dynamic business environment.

Veeva Systems beats Q1 guidance, lowers full-year outlook amid challenges

Veeva Systems had a strong start to the year, exceeding Q1 guidance but lowering full-year revenue outlook due to macro challenges.
The company's performance in margin, client adoption, and innovation remains robust, with a focus on stability and predictability amidst industry challenges.
Challenges include AI disruption impacting plans, lower revenue guidance, and delays in funding benefits due to global conflicts and interest rate sensitivity.
Opportunities lie in new client bases, EDC deals progress, and the potential growth of Vault Basics and Link products in the market.

Veeva Systems excels in Q2, eyes strategic growth opportunities

Veeva Systems delivered a strong Q2 performance with revenue of $676 million and non-GAAP operating income of $280 million, driven by product expansions and customer wins.
The company's strengths lie in its comprehensive clinical suite, customer comfort with CRM solutions, and the importance of professional services for customer success.
Challenges include short-term billing growth constraints and the need for continuous product excellence, while opportunities exist in data architecture enhancement and upcoming Investor Day insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veeva Systems' (VEEV) Vault Quality Suite gets selected by Samsung Biologics to drive quality process and content management for better visibility across the latter's global processes.

Veeva (VEEV) Vault QMS Gets Picked by Samsung Biologics

PLEASANTON, Calif.--(BUSINESS WIRE)-- #ClinicalData--Integra LifeSciences selects Veeva Vault CDMS to provide electronic data capture, coding, data cleaning, and reporting for future clinical trials.

Integra LifeSciences Selects Veeva Vault CDMS for Clinical Data Management

Veeva's (VEEV) clinical solutions will offer Simbec-Orion real-time insights into studies in phases to accelerate trial execution.

Simbec-Orion to Adopt Veeva's (VEEV) Vault Applications

Moderna

Pfizer

Teladoc

10X Genomics

Here's how these big businesses became enormous during a year most of us would rather forget.

These 5 Large-Cap Healthcare Stocks Had the Best Gains in 2020

PLEASANTON, Calif.--(BUSINESS WIRE)-- #clinicaltrials--Simbec-Orion selects Veeva Clinical Applications to digitize end-to-end clinical trial data, workflows, and documents.

Simbec-Orion Streamlines Trial Execution With Veeva Clinical Applications

Veeva Systems' (VEEV) clinical capabilities will allow GenesisCare Clinical CRO to rationalize trial procedures and expedite execution of the same.

Veeva (VEEV) Vault Applications Get Adopted by GenesisCare

Alibaba

Taiwan Semiconductor Manufacturing

Alibaba and two other tech stocks deserve closer looks.

3 Top Large-Cap Stocks to Buy in December

SYDNEY--(BUSINESS WIRE)--Veeva Systems (NYSE: VEEV) today announced that contract research organisation (CRO) GenesisCare Clinical CRO, founded by GenesisCare, has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva Vault Payments to drive efficient trial processes globally. GenesisCare Clinical CRO provides an integrated CRO model with the GenesisCare Clinical Research Site Network for faster and better designed drug development. With Veeva Vault Clinical applications unified on a secure clo

GenesisCare Clinical CRO Adopts Veeva Vault Clinical Applications to Accelerate and Scale Studies Globally

HEICO

Pool

Our indicative theme on Expensive Performers – which includes companies that are seeing their valuation multiples expand but are executing well, with consistently improving Operating Margins and Revenues – is up by roughly 64% year-to-date on an equally weighted basis. This compares to the S&P 500.

Pool Corp, Heico, Veeva: How Our Theme Of Expensive Performers Is Faring

The healthcare software provider reports fiscal third-quarter earnings.

Why Veeva Systems Stock Tanked Then Recovered This Morning

Veeva Systems Inc. (VEEV) CEO Peter Gassner on Q3 2021 Results - Earnings Call Transcript

The company reported adjusted earnings of 78 cents  per share on revenue of $377.5 million for its third quarter. Wall Street expected earnings of 68 cents on revenue of $361.9 million.

Veeva Systems Third-Quarter Earnings Top Expectations

Shares of Veeva Systems (NYSE:VEEV) moved lower by 2.2% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 30.00% over the past year to $0.78, which beat the estimate of $0.68.

Recap: Veeva Systems Q3 Earnings

PLEASANTON, Calif.--(BUSINESS WIRE)--Veeva fiscal 2021 third quarter total revenues were $377.5 million, up 34% year-over-year. Subscription services revenues were $302.9 million, up 34%.

Veeva Announces Fiscal 2021 Third Quarter Results

Veeva Systems is near a buy zone with earnings due on or around Dec. 1. The post IBD 50 Stock Veeva Systems Nears A Buy Point appeared first on Investor's Business Daily.

IBD 50 Stock Veeva Systems Nears A Buy Point

A digital health CEO shares what investors need to know about stocks like Teladoc and Veeva Systems.

Are Digital Health Valuations Overhyped Or Undervalued?

Activision Blizzard

DocuSign

The worst-performing stock on this list is up 30% this year.

3 High-Growth Stocks With Great Margins

In the latest trading session, Veeva Systems (VEEV) closed at $265.18, marking a -0.12% move from the previous day.

Veeva Systems (VEEV) Stock Moves -0.12%: What You Should Know

Veeva Systems (VEEV) continues to boost its cloud-based offerings profile with the adoption of Vault PromoMats by Bristol Myers.

Veeva Systems (VEEV) Boosts Portfolio of Cloud-Based Offerings

Bristol-Myers

PLEASANTON, Calif.--(BUSINESS WIRE)-- #VeevaSummitEU--Bristol Myers Squibb is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customers' needs.

Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market

BARCELONA, Spain--(BUSINESS WIRE)-- #VeevaSummitEU--Veeva Link expands following success in oncology to provide real-time customer intelligence on key people in 11 new therapeutic areas.

Veeva Link Expands to 11 New Therapeutic Areas

BARCELONA, Spain--(BUSINESS WIRE)-- #VeevaSummitEU--Bristol Myers Squibb is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customers' needs.

Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market Engagement

Match Group

Block

Match and two other high-growth companies delivered multibagger returns in just a few years.

3 Tech Stocks That Turned $10,000 Into Over $100,000

IDEXX Laboratories

QuidelOrtho Corp

Repligen

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why It Might Be Time To Pay Attention To These 4 Red-Hot Health Stocks

BARCELONA, Spain--(BUSINESS WIRE)-- #lifesciences--More companies adopt Veeva Vault CTMS to simplify end-to-end trial management for greater visibility and speed in clinical studies.

News for Veeva Systems Stock (VEEV)